<SEC-DOCUMENT>0001193125-12-396897.txt : 20120919
<SEC-HEADER>0001193125-12-396897.hdr.sgml : 20120919
<ACCEPTANCE-DATETIME>20120919163928
ACCESSION NUMBER:		0001193125-12-396897
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120919
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120919
DATE AS OF CHANGE:		20120919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35647
		FILM NUMBER:		121100152

	BUSINESS ADDRESS:	
		STREET 1:		9815 S. MONROE STREET
		STREET 2:		SUITE 100
		CITY:			SANDY
		STATE:			UT
		ZIP:			84070
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		9815 S. MONROE STREET
		STREET 2:		SUITE 100
		CITY:			SANDY
		STATE:			UT
		ZIP:			84070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d413985d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): September&nbsp;19, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Lifevantage Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Colorado</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-35647</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90-0224471</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9815 S. Monroe Street, Suite 100, Sandy, UT</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>84070</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;432-9000 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
September&nbsp;19, 2012, Lifevantage Corporation issued a press release. A copy of the press release is attached as Exhibit 99.1 to this report. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information furnished in this Item&nbsp;8.01 and the exhibit hereto shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release issued on September 19, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: September&nbsp;19, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lifevantage Corporation</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Rob Cutler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rob Cutler</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel &amp; Secretary</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d413985dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g413985g93h26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LifeVantage Announces Continued International Expansion </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Salt Lake City, UT, September&nbsp;19, 2012</B>, LifeVantage Corporation (LFVN), a company dedicated to helping people achieve
healthy living through a combination of a compelling business opportunity and scientifically validated products, including its patented dietary supplement Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Nrf2 Synergizer<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, today
announced plans to further expand operations in Japan and to enter the market in Hong Kong. <B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">LifeVantage announced
today that it will host a grand opening event in Tokyo on October&nbsp;13 and October&nbsp;14 to celebrate the official opening of its new Tokyo office. For the past two years, the Company has been selling its Nrf2 Synergizer dietary supplement
Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and its anti-aging skin cream LifeVantage
TrueScience<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> into Japan using a &#147;not-for-resale&#148; model. Douglas C. Robinson, President and Chief
Executive Officer of LifeVantage, remarked, &#147;We anticipate that the grand opening event will be attended by several thousand independent distributors, vendors and other friends of LifeVantage. This marks an important transition point for our
move to a complete &#147;on-the-ground&#148; presence in Japan.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Company announced today that it is exploring the
opportunity to sell its products in Hong Kong. The Company is in the late stages of regulatory and legal reviews of the opportunity and believes that it should be able to begin selling product into Hong Kong through a network of independent
distributors within the next three to six months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Robinson further stated, &#147;We remain committed to expanding our operations in
places where we believe we can grow in a sustainable manner. We have demonstrated that there is substantial demand for our products and business opportunity in Japan and we believe Hong Kong may provide important opportunities for customers and
independent distributors as well. We look forward to continuing our international expansion efforts.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About LifeVantage Corporation
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">LifeVantage, (LFVN), a leader in Nrf2 science and the maker of Protandim<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Nrf2 Synergizer<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging
internally and externally with products that dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 and is headquartered in Salt Lake City, UT. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This document contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism and satisfaction with current prospects, as well as words such as &#147;believe,&#148; &#147;anticipates,&#148;
&#147;look forward to,&#148; &#147;should&#148; and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited
to, statements we make regarding our anticipated expansion into Hong Kong, our event in Japan and our success in those markets. Such forward-looking statements are not guarantees of performance and the Company&#146;s actual results could differ
materially from those contained in such statements. These forward-looking statements are based on the Company&#146;s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and
uncertainties that may cause the Company&#146;s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others,
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g413985g93h26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Company&#146;s inability to successfully expand our operations in existing and other markets and thereafter manage
our growth; the Company&#146;s ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the Company&#146;s ability to expand its product offerings; violations of law or our procedures by the
Company&#146;s independent distributors; the potential for third-party and governmental actions involving the Company&#146;s network marketing efforts; the potential for product liability claims against the Company; the risk that government
regulators and regulations could adversely affect the Company&#146;s business; future laws or regulations may hinder or prohibit the production or sale of the Company&#146;s existing product and any future products; unfavorable publicity could
materially hurt the Company&#146;s business; the Company&#146;s ability to access raw materials for its Products as it grows; and the Company&#146;s ability to protect its intellectual property rights and the value of its product. These and other
risk factors are discussed in greater detail in the Company&#146;s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk Factors,&#148; and in other documents filed by the Company from time to time with the
Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company
on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cindy
England (801)&nbsp;432-9036 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Investor Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">-or- </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Mills (310)&nbsp;954-1105 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Senior Managing Director, ICR, LLC </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g413985g93h26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g413985g93h26.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,`#A`P$1``(1`0,1`?_$`+4```$"!P$!````````
M``````D("@`!`@,$!@<+!0$``04!`0$`````````````!@$#!`4'`@`($```
M!00!`P(#!0<"!`<````!`@,$!1$&!P@`(1(),1-!42)A,A05"G&!D=%2(Q;P
MH;%"%QK!X6(S)B<8$0`!`P($`P4#"`D"!P`````!$0(#``0A,1(%05$&87&!
M(A.1H<&QT3)"4B,4%?#A\6)RLC,6!Y*BPD-CDZ.S1/_:``P#`0`"$0,1`#\`
M?Y&^\/\`KX<366Y@I2%C7!.-4=P%_;^P?Y\<#@[`&FO2#,>%3[^_K\NGISF1
MN&GB:[C>I+N`PK&6[2``F$0'N*!1`.AA'H!#?'M,80K3Y<8@:]DH;BAIV8M?
M"7*$`^-,P?.7YQ-C\#[(.M2=.;H6LF8M%M#M+YOF(BHB=G@N^:5$[2W8)A,,
M)1HZ76:N"C[?LG4[P]:5`=DZ3Z3L;V$7>[-8+=S"5?J`'T2,01CIQ]M8_P!0
M=475K*;:P>X7`?AI(QQ<#P."I7<?!!M1Y9,M;1WW8&^3_,4IC,<-+WG:3S*6
M,X*RP&>/.PC=I^!D8:U[>(Z]^+>*'!,>X>WKR!UAM72%C;N_*7VYO`<`R1SC
MFT'`O/U5X959=+[IU)?R@[D)OPIXN:`,BF(:.('&G:-1(7N`.A:C3UKZC3Y\
MR^9\(QD0O&("H5K2F11JT0(A.*>^JBK]P5H)1^T/V#\^(R1KVJ\:1VTY/'(Q
MJ1XGLJ"T-_S`;Y]>,2FUD\K=))[:8:+E@5Y/LJOW`].G3IZ#\.G)`(8T+@$K
MO3KJ0*%^%/X#SS9&OKWHZ,:@3`;K6G^OM'BGT_KIJ[:0B4_TSY:CO`O3N^WB
M?<\Q[:31<']E4'/W=M!]!XXQT05"/;4:XCG\N!./*JQ5I3XT`/A\O]N-.)(\
MF.-3H1Y//@:MF4#[P=!#YA\^GSY'U3QE7`Z12-9&9PA!=C\E08P"`A4*4^0T
M&O\`X<FN87-';3<!:Q[L<A2*L6[EV9E#;[/VH,7"R36Z]?;0LF[I^:<'`6,H
MWNYX=FV2;E!,O:*9DZB%1'DZ:P,=E'(XJ'?,M0H]R8Z^DCXA>/:GQI;'NE_J
M_P!AY3:H.0]M3_3GY^ZH[@_J_P"'\^(L'(4GI3<_=4_<`*UZ_N_\Z<DA&Q!S
M<J\B^0_2&=1WD#T_X#_/C$4I<_2E)Z0&.50*P%^VHCZ!_,>=3O$;@"%PI^-N
ML'3PJ7NE/6H]M/W>O[_LYRVXB!0H/&DDAD^J:I$X!Z&`>M*!0>G\>.ZK:4:"
M6D=]1S'=-Q"Y\JD*A!`:4`1ITZUZ?OYQ%#:0OU,T@]]/RQ2R1:<CW=M4$,4*
M!7J(T_C^_DITC,E%1(MO>P$DC+D:OC\N<%C'XG&NA))%@52LGG-2*;99`\_D
M79?DH>^/HV#)A1\SV'MO!9+]"=:G:/E[B_(%$91..%$%$4TPEA)V":M2_;PU
M_M@NV6/<T=I?'J.`08HN=!#^I6Q;S+8.</(]$4\N[LYTX\*8#E`0`X>H""@U
M,`@(U`1Z^@\"2WTI4.12C5CQ-%J';6@Y2O4N-\=7UD!5LJ^1LFT;@NI1@BH"
M)WH0L<N]_#`<0$"^X"-/V\D0,-QN,5N,GCXU$N7BUL)9S@0Z@=>*'SBQ7DTS
M3=N(([$4GCUQ:=EJ7BI*OY5"02E&Z<BG'@FV2223,V[5$Q,:OW@4#Y<*>H.G
M_P`H8V8@AI)`4#L[3SH7V#?QNNJ`'40!Q/,GB!RIG[O+EV"PEYL,P9KNN`3O
M&W\8[",KJEH)T)##+MXMDT=)LB@L51,YA!$"E*(4`!YL>T6IW+IMMI`XME4*
M6YIZ8!S3GSK(MU>+3J1TUP`8T*`Y+ZA(IXIXQ?.%C#R.9IN_#5D8:D\:KV7C
MEQ?KF=G)%FJS]E-_&1*2(>PB3VTZ/PK7H4I>M`#F3]2=$7&T+=.FD>U<M`'$
M#[1YK6J=.]4VU]&+811L3!0X\B?L]G.N$>0C]21@;5>^)S#6#[7<YXR/`*.&
M,[),'J+"U(J59&.1RQ3=`F\5>&`R8@)R)"`?;Q_8^A3NS1=7A,<+#J=Y0[R@
MH5.H$8<@4IO>NJCM+O0MSKE?@W$MQ(4)@1G2:]6_U4F.;QR)$V=LGB1_CFW;
MAD6[)"]8AZ#ME;JZZA$2IS#%9K'N56_>H`BH4#!VA6G+O=_\<VK+,S;9(7D#
M(MP*]JX8=E4VV?Y!NA>>CN#4&.;S\&TX^V!V\LO`^LUP;2LXN1R9CF#A8NXT
MG-BJI2;B5@'YB_B)1D"QFI%4&9#5$1,'3Y=:9AMO3S3N(M;AY#N*M!0<./&C
MO=>H4L'7-LT.[B1R[*[%@W,-G9_Q+CO,^/9%1_962[3C;MMMPN)1<F9R)4SF
M0>`0RI".FCLYD%"@8P%,F(5'B;A:&%SXOK,<F2#BB>%3MMOFSQ,>[ZS0<UY+
M[ZZ@LZ;)LW+EPX%)LW2.X55*/M"DBB10ZYCJC0`*F5,PU^SE;:1.<],RORU:
M74K8V:B?TPH8N./*YK[>^*MA<[/V]Q6OA?72^Y3'T]?3Q@>3;W/.0KW\N?M;
M=;,A67=JIO1!,1H`=P^O"@[#Z@:=0,SEP(1`.."G/#QH3?O[XWEK6G0.(<<>
MS*D9N//`[NH74QA?0_:;(]CH)JJM[S6M1O!,7B8'-[2S)DZD%'#MNLT*"I34
M+U&E.2/[;M`0'2C5RTCYZ:'4=TF##_J/S4N#23RC:][MRUP63:I[EQUF2V&I
M7EP86R9$*6W>;)L0YT5W\>F=1=.38BHB(%%,U0]1``'E=N6PNMFM?$5B&9`0
MC%`H7+MJVVK>FW1D%R-.D!%*\^RMZRMY"\(87V)E-?<C/EK1<PF#)[/TQ>LN
M=,L`PM&!FH.!78E*0QW"\PZ?3:944"D^JAJ#QNUVF9T7J(2I[,<4S6F[S>(M
M>B-P'<3V\$H=<WYO[[N!1]<&`/'WLIF?$+59?MR8A'QUOHO(ULKV.)*-B'KT
MS]ZDL2IT!*`"8M!Z>G)5[M$;;8D2??(/*@YC+'A3=EN$C9A+(%C7-3R_3A1#
M-&?(G@K?&U)I_C-Q,VU>UE."QN1,6WLT-"7U9KX![!"1CU3*&.W]T!+[I3"`
MT'C5SM\EH`]X5KLL.*9)\E1[?=&W$CVL*$#GVYY>V@3S^Y[;2SS/[Z70YPOE
MS,8WWB;$4(G&XFMA&X5X<8B2._)(2Y3OV8I)K`X[2FH/4.$$EK%/M4)D.G2&
M^*M0BA]MU,S<I"S$DN'^X'X4;72OR(,-RYN\X5#7[-.&`LV+9R;EYE6W#6^E
M)B[$2BA&G(X=^Z*?J(!U#Y<'I]FMXF!T;@]Q<``@^>BYN\W+BFA,%^E^JDP9
M>\X>(+6OVZ,6X%P;G?9J];.F7,'<!\?V4NE;+"3CG:T>_CC3<NYCRJ+M738Y
M#&!/M$0J`CQUFPPENJ1[6GL'QKD[U.N$>'\7ZJ^;B/SFXEE,D0N+-E\&YFU)
MN*Z))",MN4RI!(C:$@\>J%39LAN%J]7;IN%U%`I4O3TXDVTZ(TB.IG@!\ONI
MF#=@^Y<U^#ER4E,.ZC>NIZ-8Q1I=X_CV\:1BI*+RIUTQBTHM%'\0K('>F[42
M-OP_U@:M*<JHK4.?Y!BH"9%>7SU<W-VV.)2G?X4#?+?G'L1O?\SCC4O7W+VX
M,I;#]:,N"=QS&)(6<W>MU!(X;-[G>KD0743$!IVDH(!PFM.G;6YA,M]*(Y04
M`0$>\T(774-U#+ILV%\>))#B,5[JZ#KKYE<4Y5R)&83SEC+(NI^9)_W$K6M_
M+,05I;=R.RD,H>+C[J154CU)(A$PH50$RC[@4'X<8O>DHPW5:.$C3FC0OABA
M]HJ5:=5O_P#I8A_B/;GA2T]0-S+#W$A,M3=CPTQ"HX?R[=&&YQ&4%%11Y<5L
MECU7SAF*"BI%F1P?IBD;NZD&O*'<.G);(L.IPU+P'#Q[:N+3J.*Y+F@-U`*B
MGAARI)FUOEVQ3@'*3K`.*;!OO:;/\>JV4FL:XAB47W^*H+@5027%/+NF\>T4
M,V[Q[.XQB"'4*A3DNWZ>E,0FE<0PA0H'OQPJ%/U,1-Z43%<#]H_-C7*L3>;>
MTELFV_BK;G7'+>F4]=TDA%VE<626J4E8<BZ?*E;QS=S<\<8[5J^=.#E*5,Y*
M`(A4U.O+-O38FM9)8'ATK&DH@X<BN!Y57.ZJN&7D44L9;"YX!.HX`YJ$QHX;
M)^F]9-7<:Z3>,WB`J-G_`+A547!5"@HW=(*D$Y%&SA,0$@@-*#P2GCN+1Q8Y
M5!0CD:-89K:\9K8A'8.%;#QVO5YJF?DB?]S%/&,3J;R$XH$A^XU4S@^Q^'ND
M#NIW@`4H(4H//H![)(?\<VDK(VN#K7%>6I*P'<9(CUO/'+(YOWCD0?Q5Z2]!
M(8Q2?47N$1,8>HB/J-*\P"7UGD>4(.VM\LXX&0>5[B%.=<)VB+W:XYU*8/I_
MZ27^8?0:]MMONE!^`UX]MDLL.]02.:%:0@\14+=88KK:IXVN<$/#L!YTQ8_2
M8)B&[&7OK$?_`*+7$H]I`$I#W$W`4PH4/H`2U^=>;=_D^*-NT6TS0-3Y'<$R
MTUBW^-I)'[O-$20&M;Q7,.7Y:2UL'8EHY)\_MPV!?<2WGK,NO:N*B;B@W8&%
MK*1ZK1LDHV7[3%/V*`6@]H@/4>65C++L_2/YC:DNG<=*$H!JB#E!&*@C"JS=
MHF;QU3^73^2)N*MS*2$(5P0KC3I?R48AU@\3FC&PVP&K>);=QEEB];3C,,PT
M[$FDUWSE"_YAI%294R.'3L$U6<:X462,0H"0Y`-4*5#.=@N[_JC?1:;C*_T5
M+CYB<0%&!)&!"UHNZ;59]/;$+FSQF1HQ`'UD56H<C0-/T[FF&IN5T<I;6;:S
MV/[A=Q]U-+;QU:&1+FBDBOESD*[E[CEV$O()*R#U5Z(D`JA3HB4>H<,^LI[K
MI^W_`"S:]7W[$U_10$*0H0*?D4T"]+PQ[O?"^W%[]5N\.T'S!Q:Y$Q7!/FI<
MWGMT>T5N[56X\_:[O<,VEE?$BK.8E8C'TO;;<+PMXP"D]9$B(EW^'7>,P*`E
M,FEW>M1KRBZ8WS>PW\!>-$D+@H<YQ):@`3-.T+B>=$'4.V[7*_\`&VYT3@_1
M:T`%22N2X95VO].%F%3;/QW9>U;R>[--!C67G;!;$DW)9(Z6/KSB$5H!N/O'
M5(H6/="X(C6O0@5J->5755C!MEQ'=6\CR]Y(/!-(&1'8<:O.F)CNK#:3L8(0
MF.9Q)X'N]E*T\'-YS6-+;V5\?M^.5$;STRS#,VY!(OCG_%+XTO1TXN*T7K)-
M7^V9DDF\``%,/;`YA#D7J.QB$$%U:N+V/A;J.&9:OCQQI[9+N1EW-;R`#1(X
M#/(.`'=PI9/E@V47U?TIRM<\0O\`_,[R;(XKQPT3!1->0OK(@#;\*U;BV`JQ
MU2*.SJCV5,`E^5>4FRVK)+A3R7AW5<[K?2!OI$`+Q4]GZ&J=`]1+'UVT)Q-A
M+(5MP,VW5MEO?>44;NCXMW'SM^W(9&=N&4FR2"2C$')7YP,)S@'4M1YSN-U=
MS;LYMF#Z+6AH()!7ZR`')<<J>LH+"WVUKKLCU"YQ*M!YIBAK9[B\E_CPQ4^&
MSYW:3!MJ.(@3,$X!K==O(MHE)FJ+86)&D:Z!JB"2I!#M`H``=/3G,^W;HTA[
MV*N9+@3\JTL5[M+P6M<G9H0?)0:M^LQ:JO-L]!-RM4,I8RNG)3C.$?B;(2F-
M9Z!>3-UV)=<>9(JDQ'Q+A1<P,G29A`RJ8%'N'J(APNV2VF9MU[+=C61$$#CJ
M&)([4\*&-WOHOQMM;6B-$DA#BT%I1`1D@.-8>[>L\5M/YW=:\8S[I\ZL!M@6
M8O?*EO(O'2#6Z;3MNXV9D[>DO;53[XI2:<L%%4RB'<<@5Z=.1/Q7H;$R=K6A
MS06Y=Y7V^ZN;>S$V[F$O?H./^X<Z="Q-OPULP$?;MO,"0D)#MT8N(CHA$C1H
MP:,4BD9HI((%*F":"*8`%0H?_FK7@8;N1[VR/`<]PQ7'O3EX9<*/H]N8^)UH
MUQ:"F(0'#']5-[-D+"B=7/-=I5EK';-"!CMNHF]\79<CHL@,HVZ)>-C7;B(F
MY1BU`C=>4!T8O<<Q``0Z^O"[;Y/S;:)73'3)`UQ"=GT02>SCG6?[K`=BW5D,
M)+VREH.K#/$H`@^"5T/3DH#YQ_)20!4*7_H-A)0X>\J8AE#3KDO>5(QQ32-[
M="U(`5``Y"W5Q;M,"8_1_E-6.VV[?S%[R2KF$_[AAXT>KO$2>V8Q3?4<H#V@
MJ<2)G$I$1%7O]Q<*5&M>"<=PYY^[S[THXD;"WS2-;[%I&^0=CM'=.%I%K?V3
M,*X3DYZ74DI:/>RUNV]+2$J_4.Y7>/VB2K=\LHY7.8YC&`0$PB/QY;1P7UPP
M*I:>;OG-5<U]91'2&MU#]W]5#SW?V$\:N^FJV9L<K;#X2O*XFMC7)<U@NFUT
MV_\`G\)>-NQ;R0@96VECNR/".B/T"E`I!$#?$!Y=6%K<QSQVY;]TY5Q!X+ED
MH3,4(W]S$V2:]C/W@<$:A`"H,\\E\:'1F+;C,=^>&'1W%ELW))1V5]LKLL;6
M.0NM)15.37AXITW87)*-W1B]%9&)(("KT`X&&@\L+G;H-OW-R8M:QKL?M/Q/
M@@IBWWFXW*S1S6M)<1@3D,!GQQ-.6-2=7L5:D80LW#6*+9C("%@(9BC*OF31
M)&0N&;,V(>3F)20*`O7KYT\4.8QU%#"41[0H`4X(WNXNNYGO?Y8F.T@#+O(Y
MT8;3M3+:W#@-;Y0'$E%!(R'96M;I:A8OV_PG=6.[X@V!9G\M<OK,O9!JW3NN
MR[F9H^Y%3$!-=I'S1T19(H&`%`(H7[P#0./;=NCX;ID8<XQ%R$*4QQP&6=1-
MQVYKK:272T/:U1@`O>:;9>,',-XZ5^)[R19$NB5<R>1,/["9>@6\L\'O</;K
M3AK;MR.DCJ$#O7D%R&26$>M5?3IPQW&RFO=PALH?,!"92IQ(488\%`H9LKB*
MRL7[G*!K,IA`3#$*N&*T8/P_:NV9KKJO960[O<Q$OL5GN.+E/,V0Y-VW=7+(
M2-VG<RL?%GE'JJCY..C8]VB0J93%`#F,`A0`X/;P[=6N_#>D3$SAP.151GGW
M>-76U3;9(EP]P$A_=RS'+LI6.\FO6(-O=;,G8@OD8"74D[9E7EG/%W3,[VV[
MP9,5G$%-13P5`6;.V\BBF<#`8*4XSLK]X@OH]$)T.>`X(4<%X@<OVU)W>79I
M[9XD>&D,*.#0HPX89\>^DB>#W.]T9ET7MFW<B22DWD3!-U7=AB[)%=R=8SS_
M``R:>Q]NNEEC&JHY=P;=$Z@AT[A'MZ<>ZUMY["?UY8XVOD0Z0B9H<J8Z3N89
MB8+>21\;"1J*JFG#QSHTO!FBZO-4S^H'_<RSA#U*4OD%Q8K[HA_:[4Y#'I3D
M$_P4`5`Z4].?0+KB9W^.[.!@!'X7E^]7S[NL,7]Z7$KRA$IX\]5>DJ19,P&[
M#%&BABC4Q0Z@-!#J;Y\PB1DH&`\R=M;E875KZ1"GZ1Y<ZX5M&LF76_.PG,4.
MW$>0CC0P#](6R^J/01^7.MJAF_',DE&/JM`[B>VF-RN86VLC(BH<TD^PTQ>_
M28B'_P"V<O=IBG`,!`K4G6A5+C;F*`^GU4-U#FO_`.2YM>T6K?\`J/\`A63_
M`..(=&\7!_=9\CJ3[DWL6_47&`O<H0NWL8D?VRB804*R3.4@!TJ/<8/]_ER^
MMP']&-C=]H'_`,54ER#_`'DYPY'_`-M.E/U*]A3MZ^+F^I2&;K.#V!?6/+OD
M1;&'WFT6$VUAG2HD`A^X$5),IC`(4`@":H4YE?1]PVUW\/7`AW\IK4.J&/FZ
M=#1R;_,/FIJ[X??$=8WDNQ=D*15VDN7$U_V!=QH23QO$QSIP)(5Z":\;<!DF
MT_&F61=E.`"H4GTCS2^MMS%J^"[,1?$UVI5``+6X`@@JHRQK,>E;3U)'6<;P
M'2-`S*JXA<4P3CRHNMQ_I5[*@H.0D[CWGN6+MQH+Q:27EH60_)D&ZPB5TD[,
M\O'V3I@:HT-P4@ZZ\RQ6H)3L'NHKN^D)U#3*W_6?FHR7B&\5%J>,Z%R@ZM+,
MYLP1>8TK6D6K_P#)0CT4F,*W<"Q=LU$Y203<HNBO1$#`(5``X%=4]0NW-K2Y
MA8\*43L`3V4:=+]./VL*7!P."ZER)/*N-[<)%TN\L>KVU\:W69X\VX9+:TYI
M.@7L9A=J()RF.9V0+]*117<E,U.N8:I@!0H->6.SR#=-G?:$D/:TIAC@`1@O
M/!,*K=QC-AO`F(&AS@3VJX]W*KFX`#NQY5M7M06Y1D<8ZK1CC:?-+<@B9@I=
M"8(,,=Q+T0[TW3C\P7%0$C`02D`3]?3B6(%EMDEP[^HX!/`D`?/4C<&F\N(_
M2Q`5?C5WS!3^0LNYOTR\>5CW5-8]M;9^Z9*2R?<MO.SQLL>R;/2<+/(:/?$J
M*!G2;<`[2A40^/(_3UQHMCN,B$ASAEEI*GVTN\P-DG%FTD#2U<>8I<.+O%AH
M/C6UHZVX/72P[A:-V2#<\M<K)2=EI@Y$"D=2+^0?*G4>O%E`$QS%!,`$:4KU
MY#W+J6ZFD]-WD<N0;V_HOPRJ;MG35O%'ZKB2U.+L,1W4'7RS:6:;:T7IH_>V
M&L:0&,LEW9N#CU@!K<<.42NX4B+Q9\(1*JRR1D43G+]1.WM$P\*M@NKBXVJ_
M]8#2V)H!1%.HKXT,[Y!!!NMDV(DGU7*I_="4LQT8JWZ@"Q2E534(GHAD(QTR
M$^LBALC6,43**5]%R$*)0^-!Y6W8T].@?O?/4W;R/SD+]G_B%'6.17VS""@)
M`=3W3!]Z@B<@D*4>GWBIB`_MX&1XN9R0UH<1#923C0$?)@IW>3GQ!-Q,1!,V
M6KT.("(C[BPQBOME+0*=QS^ORKPMV!WI[5>+QC=\E`/4[/4WB!HQ\S/C5.GR
MQ"^<GR6B4?=]O`>#:E2`3''NGW1?I`:=W:)>ORY'W#S;7"WCA_*:?MDCO7<O
M3/\`.VB/^0'/TEJ_IIL9G.!:@-RV)C^5F85%6IO9F'A$8J/>&*%.TJ!G)#B'
MP4`0^W@YL-L[U!ZH\O'P)J^WR8"$AA\R8>[]E#*\9_BTP-/8&QULALS;;;8#
M/F<K7CLD7-=&0G+N=:Q7^4(HRZ<=%1RZ_P"&0*T_'4K0:`-*!3A/N&Z"W!CB
MP:U%*!53(=E"=EMDUU)J<<"O$Y+2E]LO&9H([PCEB\[AU\Q_;B]FXVOJ;83L
M*FO;CB/-'VS)JHJK.&KGV5RJ+T[:D*`CTYQMFZSRW,+H_,2>(7`YH`B(%YU*
MW+:1#:2AW(?6[1V8TWMDK.NJ(\*?COV>LN&?2B&H.Q#+*$S$-455W(65_D"$
M>_<IH55.Z*Q8F[C"(E#LJ/2G+W='&;>3;CZS(_B*JMKM1!M)G=F'/]R'XFGD
M>#,PV)G?$ME98QY/L)^TKQA&$Q'OXYPDY03%R@F9VW5.D8W8X:N>]-4HT$IR
MB'`;=-KDAN'0#Z:KGGQHXV;=(Y+4:^`'#D.^OD[*Y\Q_K;AB_,OY(FV4+;-I
MP#U\=5TJF59^_,D*49'1J!CE4>/W;DY2D3+U&O%VG;'S;C%&"CB_V)SJ+N^Y
MQMVZ=X`+!'RYIV^/A3.C`P79L3X/?*)=;6)>I3=V;,7[E%Q`?ACD?GBT'%I3
M8))$`PF;*FC42&,82F[*&`0'FK7KSL^\0S%//9Z>?$'LY5GMG(W<MF?"5TB[
M+N63?'G1(]2O#AJOL'K?@_,MO[-[?KM+ZQM`2B@0F8&#.+2<BV12DX]!@-JN
M19DBI,IT0(*AA`B8?LY17_5$[97,$3"T',\?"KG;]HB+!YBO?RI1H>!'6V@F
M)LON6(`!Q$Q<SL3E#M`1-4!LZ@@`?#X\J6]<W%O(`V-FM</+Q]M71Z3AGC)<
MYQ81CYAE[*7IHMH/ACQ\X^NC&>%I.]):(O2[%;YEWM_33>X9AS.KI^PN8%6T
M?%D%11/ZC!3J;KREWS?9M]>UURUHD:N0(S*\2:LMHV*'9P3;EQ8X\7`\$X`<
MZ7]RJJZKS7O*#H]OY,^4[;7..#\#YA69KYV3O6P+^LENW8E42AHBTW;2X(J1
M1DFSE18KQ@8I*`!^\G0.G/H[9-VL6](V-K+(P/;",-3`?I<?,O#B*^=^JMKW
M";J6YN((WN;K(4M>1BN7E1`#PXUSH8W]0D43`:X-W5ZF$Y55[QG3J'*8>XHF
M'\^,(=!]/AQ^V&SOB(=)&,#_`,QH^--,9O,3$$<G_;=\U%^\0]O>4^:NG:R&
MW'#86X+1E=7K^CK+C<L3DI)P;R\7L;((-FK!)S(/B_F:Q#%*2A`]?7@;U"RP
MCFC=;R,(]9BHX.^MGG@.VB/8';C)',VXBE7S)Y'##3W5J7Z9K3G:#7;;G)MT
M9OPE>N.K>DL))QD5,W*S(@FY?J2K)R+-%9-9:H^T`"":@D,6GW0Z\@]=W4-Q
MM\`BD8XZG*A!^SR)2K7H:TGM]PG,T<C1I9B6N'VN8"UQ+(>CFW[[SN*YK:X'
MOE?%I-H(>YR7N1%1.%)"`@F123!4%`2,1,`^_P#=#KUX0QW]JSI0-,L6OEJ:
MO]+DJU2#;[E_5;GF*7TT..ER?U.#DI]3E3%EEYHQK>N++[AFDW:5_6U(6S<3
M%TB"P+LY-FJS6,!3$$OOH`KWIF`:E.4#`-0KS#+:]FMMSU1Y*>&&7.M=O+)L
MVU"(K]$=^8/?7GTY\\9_DS\1VQ,WEK2EQ?UP8_=2,BZ@+HQPS5G'7^-KF6,U
MM^\;4651/,$BTNT`*H18AP+2O-PLMQVS>K1MO=21^DX@.:YS6D>_AS&58^-M
MO[&9\L$<GJM"M.EQQ7#A6J7MF;SV^3G\HP7<=O9-0MB7<,HR21BK&<8<A3%,
M8J:CVYGAVL&1R9'J8XA[I>@]>6-QMO2.UV;IH7Q:P,=,H)([M2U$;+U1=70:
MYK]*G.)P&?\`#QI\9XV=9,IZF:D8SPSEW([_`"7?=N-C.Y:=D%EW0QQG12&"
MV&:[@QE%8Z(IVIB%"#7IS#=[W>R_%DP1S&(M3#'@"N?A6M;=8[FVU!>Z(/7D
M>!.")7R?*%K0\VETZRG9%M1!7.4K39-\F8@=LQ,@Z9Y#LI4+@MX[1P()&37=
MN&!D3`41K[@!UKR3L5VRWOF%=,3]*KP5P]_.G=^M'2;:90-4[0<E7RM)RY+\
MU(]\*VOV<[9Q_ES:C:^$>06SNQ]Q1C>ZT9%-8\I$6=9\:6&MN+*8Z93$*H\,
M9<Q2@!?01'D[KBYAAF9!9D."$^5'`8A,0O;55T,R>ZBD?=L>QS2U-0+"B.7-
M.5=)\K^F>;<\-L)['ZK2C6-V?U5N_P#S*Q&4BH9!E=T`8BI)RV3N/;5024D$
MU!``4#M-7D39+Z&!_P"72C[EZ8E$5R`@DU/WC;9)VG<(OZ@4)BOE!3"DR1/F
M<V#B8PEHWUXW=FDLRI-4(YXQMV$C7]HN)A(H-U7;2X#S+=JA#.%R]P@4`-]0
MCV<N[C8;)CA<,F869Z=0)0\%SPYU2VF[[EI-L8I`,E],IAARI%.S&K?D>VZR
MGJ9N%FFSI&V%+2V0LME8FM]MN&DM&8UQX)'IYV^[O7!5NT5D)9O[28@`+&1,
MC0PE`0K;V5[M\6UW=E&X-<(]6)'F)<IQ57%$\*J+JROCNMK</8YP=(04:<`&
MCL0?MHMKC#V30\U=F9L+9LV7$[73>\+"<7L5!L6"5NQU?=LR#&,5]E<RZ;PS
M-@N8HG3`O:4>O4*C]U/$_8-`<WU->(53B%[^-7ME!,W>-18_0&YH4^D/"C(G
M_P#9,/9WB0A5"D$*U.F4YR]/F!@#@A#])@RS'MHZ/TG&@R[]X8RK?_D&\8.1
M++LZ9GK,Q=DJ[I&_95J*8L(%D^BE"I/7QO>`$B$ZB6H!4:%"H].$6UR1QV-R
MUSV@N81VY=N="F\P/EW*![6N(!:N!3,\J39N!:&TNB_D&N#?_`N%[BV%Q/G#
M%\#CO-V/K36:)W)`JVL]_%L)B,9N7")WRQNIB^V(#4:#\>/Q36]QMOH.<T2M
M<T?!<??4&]CGBOVR,8\L+3D"1GE2CL;YEN[RHX8V(P?E?5K+.O>+[NL3_$X^
MX,AF9-)J4D'YUS-UR,V4H\==C-^U3.8U1^D*CZ\>DLX-MTR1RL?(''!<",%1
M,D&/;4K7-<KZD;QAGI.!X>WCRI#.OVW>\_C'LB*U:VCU)RAL#:6.4PM_%^;,
M,HM;F2FK.15.DPCYA@LZCGZ#ALV3(`BH0:_,>/S;+9[F!+%/$UAYN1>10XC]
M%IV&_FL@GI2$CDU4KZV:<A[]>53&]\8LL#!-[ZBZTN+;E)"\KPOPZ#/).4F[
M*,D3EQW;<"Q</7L6UE7WM%%115NF(5Z\DV.U[=M=Q"9I8W#5I"/^U@O)`JDG
MAX56;KNM[>02I'*I3#1C@1R[J7KXG->K@M#QFXVU]V`QPXA7GY;=-N7A8%S&
M1D5EH9^X%$J;T?<<)]SAJ`"!A'U]!Y3=0W;8-^:^U<UQ`8C@0X`A<T7#G5UL
M=GZ^QN9<`M)UX%6G'OYTC=]XD-R=5+UG9/QD;@IX<QA=4FK-JX1R9&O[JLZW
M7KPW<X)"QSMM,L46M3F$`*F3ZA].6C=YL+V$Q;@&BX!5IP+4&:<<>ZJ6;;Y[
M29HMP71EI4@$IWE,.ZM_Q_XO\UW3=9L[^3?9T=C$,<L9&YX+&,0W>0.)(IVU
M;K+.Y*5MY0D?%.2HIMDC$`6QP(*=>G(K;_3?1#;AB'A,`G;A[:8?8%]C-^*!
M`T<5'&L?P7V-;U^ZH;4RDK;*#K'&;-H\X.HIMVD&/G[,77;VZ";!(/[18LC1
MG[:0EH0P!]-:<F]6[I)+N$#FX%D0S`XDTYTQL<;]LD8XM4S.XGD.RN$V?;^]
M'AIO&\K#L##5R;::&3]Q2=SX]CK.=MCWUA\\\X4?/;;:13Y9!PZC45CF$`(K
M[=`Z?4(!QNU9MVZQ>=[8Y\,20$SX$XBN+VQN["1&-UL"X`./+LPK?KM\GN].
MUT>OB?2W2',N.KGN!(T2]RSF..B+7C++0D""U=S#%%_(KK.'$210RQ.TG<82
M!V\2;8MMM0;N2>*1L8U)J`)3@`#B3DE=1;AN<T?X:.-[2]6XL/'#-,*(99"V
MQ&FNN6`L?7D\N7:+*CJ4,SR!?+I-91R@ZF'(+N7BASBLJ#6+.X$B=:`)"<HV
M0VNY7KW*&,1Q&IR<%_4*(X9+K;[%@>"YZ-'E"YX944?E%5[6*=,1,8>RM1K6
MIOX].)ZDHP&51GA^HH"E4^V/]`_Q-_/GO4EKE).1]]4*%6`I032`P":I^X1&
M@4]0`1X]$Y5,A0\*D0Z@#JYU,$S$.;L()2B`&"G<("<:]W=U'G6H%N)"T\M0
M*7>;N/[HFH):!W]G;6M*>E!ISEY&E`B+XTA/"IBG0HE#W"D^FHE`W>%#5#MH
M%?4.OV<:KFH52]TAB*$$Z9BB!J@/>):?TTH81^5.(@.=*IJPDW*W"B2((%I3
MO;MR>Z8/_4'MB/[>G/(!D*\I-7NP_P#2;^`_RXM)4CE5/3O`U`'Z>TIJA3T]
M`Z>G/5ZI@4]`Z'&@4J8#"/[Q'KSU>J`(8!$P>Z!AI4M#=@_;Z4#IQYI&E"B>
M^E!J0H&,(&,B41Z5$3GJ'7X?5TYUK:,C[A72FJP3'KT.'2GT@8`Z^OH'4!XW
M(04KDFH]L2A0@*4'U+0U/X4I\.-TE6S%5`HB0IN[I3H/Q&@_#Y<]7JJ*03$'
MW/=*)@$#=H'`?C\`#J(#SU>JOL$P%*)3*$I3^YW%-Z?$>@\]7EJPFFJF7L!`
MB:8`-`)41"M*_$>226$KJ4UTM2.U(L?M53,=,A0,F!Q.!>\*?(0#B:T;F-2U
MY<:K2(H!:'()1#T*7N$I:>@%&H]*<1^AP3`BN@R+!_U^./ZZ2MN3AO*&<M?[
M_P`<8>R?,88R'/-62UN9&BFHOG,/)Q[I)PV2,S(@NLLT<F)VJ]!`""/)FVLL
M&7#1.UIC/:0F*J2J9<.-0=Q]7TS^'74G`+PH-UM[=>8O4ENGC_831R6VKCXK
MMCF&8L"A(7!*W#'M"_AV\E)6Y$KOUH]X[(4#J%]E,:]:!PK.S=-[FZ.YCNK>
MWTL(1SD<5["<.65!T^[;[MP=#%:W,VLJK6X#ARSXUK>3<B>67R7P#C`UM:Q7
M#H_@VZSDC\FY2R69[#Y#6LY50I9"+MN`D%$'POG[<ATSB5`P@4X5XS`W9]FN
M_6;*R<M(0M<.7#%./A7ISO.[6GIR1RQ$@@AS>WN7A1X=8M?K,U;PCCK`N.8]
M=E9N.[;:0L5[R28.'@H_W'4D^.DF032$B[5455`]3`)OAP4W/<W7^XN!C+6H
M2'`JU`2-*\^.%$VS[7)M]H-<C7$G+(J0.'+"N_B0P@)3`H!!IW`4@FK00$/I
M$!`0K]G(56M63$$IBE#WT2"<.C9N`E.%1J"PE2$2@(>H]/V\1!7E-914$Z"(
4$$YA'J*O<`C_`!XM>K*YZO5__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
